Page 2 - Dr Reddy’s Laboratories

From DRL to Glenmark, pharma companies see steady revenue growth in Russia

Strong sales in Q4 during war aided by 'stocking up of inventory'

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

No changes in Sensex composition, Dr Reddy's remains in benchmark index

The market was expecting Tata Motors to replace DRL in the 30-share index

Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

Dr Reddy's plans new brands in Russia, says no issue with funds in country

The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.

Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.

Dr Reddy inks $61-mn deal to acquire Cidmus brand in India from Novartis

The acquisition of Cidmus is yet another move by drug major to widen access of healthcare professionals and patients to well-established brands

Sputnik Light may soon be only version available in India amid low demand

Meanwhile, local manufacturing partners have either halted or reduced production of Sputnik Light owing to low demand

Valuations turning attractive for Dr Reddy's as company outperforms sector

US price erosion, India growth trends would be keenly tracked

Dr Reddy's falls 3%, hits 52-week low; stock slips 10% in one month

The stock of the pharmaceutical company, which has a significant presence in the Russian market, has fallen below its previous low of Rs 4,135.90 touched on March 19, 2021

Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's

During the transition period, Dr Reddy's will continue to supply the product to Binnopharm Group to ensure availability in the market

Dr Reddy's Laboratories launches generic drug in the US market

Dr Reddy's Laboratories said it has launched vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.

Covid-19 vaccine: Hospitals see no immediate rush for Sputnik Light

Dr Reddy's Laboratories, marketing partner of the Russian Direct Investment Fund for the Sputnik V and Sputnik Light vaccines, has sought government approval for use of Sputnik Light as a booster shot

Trying to bring Sputnik M vaccine for adolescents to India: Dr Reddy's

Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a COVID-19 vaccine for the 12 to18-year-old category, to India.

Viral vaccines, vector platforms may become new growth areas: DRL chief

In a Q&A, the chairman of Dr Reddy's Laboratories dwells, among other things, on the draft R&D policy and the first-ever Global Innovation Summit of the pharma sector held last November

Here's why HDFC Securities is bullish on HCL Tech, Dr Reddy's Labs

Nifty should be held long with the stoploss of 16,650.

Dr Reddy's may underperform over concerns about launch of complex products

For rerating, it needs sustained growth in India, recovery in US

DRL plans to start paediatric trials of Sputnik Light vaccine soon

Booster shot with Sputnik trials may also begin

Germany's Boehringer, Indian pharma in legal battle over diabetes drug

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

DRL steps up Sputnik V supplies with second dose from Panacea Biotec

Hospital industry sources claim they want assurance on shelf life of imported vaccines